Joan Em Van Der Lubbe

Joan Em Van Der Lubbe

Johnson & Johnson Co. - New Jersey / United States
Medical and Health Sciences / Immunology
AD Scientific Index ID: 4458457
-
person_outline Joan Em Van Der Lubbe's MOST POPULAR ARTICLES
1-) Ad26 vector-based COVID-19 vaccine encoding a prefusion-stabilized SARS-CoV-2 Spike immunogen induces potent humoral and cellular immune responsesR Bos, L Rutten, JEM van der Lubbe, MJG Bakkers, G Hardenberg, ...npj Vaccines 5 (1), 1-11, 20202522020
2-) Ad26. COV2. S protects Syrian hamsters against G614 spike variant SARS-CoV-2 and does not enhance respiratory diseaseJEM van Der Lubbe, SK Rosendahl Huber, A Vijayan, L Dekking, ...npj Vaccines 6 (1), 39, 2021612021
3-) Immunogenicity and efficacy of one and two doses of Ad26. COV2. S COVID vaccine in adult and aged NHPL Solforosi, H Kuipers, M Jongeneelen, SK Rosendahl Huber, ...Journal of Experimental Medicine 218 (7), 2021602021
4-) SARS-CoV-2 binding and neutralizing antibody levels after Ad26. COV2. S vaccination predict durable protection in rhesus macaquesR Roozendaal, L Solforosi, DJ Stieh, J Serroyen, R Straetemans, A Dari, ...Nature Communications 12 (1), 5877, 2021332021
5-) Mini-HA is superior to full length hemagglutinin immunization in inducing stem-specific antibodies and protection against group 1 influenza virus challenges in miceJEM Van der Lubbe, JWA Verspuij, J Huizingh, SPR Schmit-Tillemans, ...Frontiers in immunology 9, 2350, 2018322018